Select Page

Filament Health completes the first export of botanical psilocybin to Australia

Grow Opportunity, Media Partners

This post is presented by our media partner Grow Opportunity
View the full article here.

(CNW) Vancouver — Filament Health Corp., a clinical‐stage natural psychedelic drug development company, announced that it successfully completed an export of PEX010, the company’s botanical psilocybin drug candidate, to PerthWestern Australia.

The shipment is believed to be the first botanical psilocybin to be exported to Australia and was received by Reset Mind Sciences Ltd., a psychedelic-focused subsidiary of Little Green Pharma, a biotechnology company dedicated to developing natural quality medicines to help those living with chronic conditions. Reset will use Filament’s drug product for research purposes.

“The successful export of PEX010 to Australia is a major achievement for our team and demonstrates our significant regulatory capabilities,” said Lisa Ranken, chief operating officer at Filament Health. “To our knowledge, this is the first legal shipment of a botanical psilocybin drug candidate to arrive in Australia, and we are pleased to see a natural option being explored by Australian researchers.”

“This shipment of naturally sourced psilocybin, the first of its kind to Australia, is not only a significant milestone for Reset but also for Australia’s burgeoning psilocybin industry,” said Reset’s chief operating officer Leon Warne.


Since July 1, 2023, authorized psychiatrists in Australia have been able to prescribe psilocybin for treatment-resistant depression. Reset is progressing its GMP licence application to manufacture psilocybin products for human consumption from botanically sourced psilocybin while the industry awaits publication of the Australian Therapeutic Goods Administration’s Therapeutic Goods Order governing psilocybin production in Australia.

This post was originally published by our media partner here.